Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) EBITDA (2016 - 2026)

Protara Therapeutics' EBITDA history spans 14 years, with the latest figure at -$18.2 million for Q1 2026.

  • Quarterly EBITDA fell 54.19% to -$18.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$63.8 million through Mar 2026, down 40.67% year-over-year, with the annual reading at -$57.4 million for FY2025, 28.7% down from the prior year.
  • EBITDA came in at -$18.2 million for Q1 2026, down from -$17.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$7.7 million in Q3 2022 to a low of -$38.5 million in Q4 2022.
  • The 5-year median for EBITDA is -$11.2 million (2024), against an average of -$13.3 million.
  • Year-over-year, EBITDA plummeted 270.43% in 2022 and then soared 73.82% in 2023.
  • Protara Therapeutics' EBITDA stood at -$38.5 million in 2022, then skyrocketed by 73.82% to -$10.1 million in 2023, then dropped by 26.86% to -$12.8 million in 2024, then plummeted by 35.67% to -$17.4 million in 2025, then decreased by 5.05% to -$18.2 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's EBITDA are -$18.2 million (Q1 2026), -$17.4 million (Q4 2025), and -$13.2 million (Q3 2025).